Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Follower s Follow Play 8min Summary Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares outstanding sold short. Considering Crispr's secular growth in the long term, perhaps short sellers are betting on near-term negative catalysts. Vertex is exploring an alternative to using Busulfan, which is used to clear out existing patient stem cells; finding a less toxic agent could increase Casgevy's patient population to 150k. Andy Introduction In 2023, Casgevy was the first (alongside Lyfgenia) gene editing treatment approved in the US. Casgevy is jointly owned by Vertex Pharmaceuticals ( VRTX ) and Crispr Therapeutics ( NASDAQ: CRSP ) who's shared interest is split 60-40. Casgevy edits patient stem cells to treat sickle cell disease and beta thalassemia by editing the BCL11A
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Ark Next Generation Internet ETF vs. Ark Innovation ETF: Which Is Best for You? [Yahoo! Finance]Yahoo! Finance
- Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear? [Yahoo! Finance]Yahoo! Finance
- Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% [Yahoo! Finance]Yahoo! Finance
- Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 8/12/24 - Form 4
- 8/5/24 - Form S-3ASR
- 8/5/24 - Form S-8
- CRSP's page on the SEC website